Lintuzumab
- Generic Name
- Lintuzumab
- Drug Type
- Biotech
- CAS Number
- 166089-32-3
- Unique Ingredient Identifier
- V00Y10W60W
- Background
Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT02998047
- Locations
- 🇺🇸
Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer CEnter, New York, New York, United States
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00528333
- Locations
- 🇺🇸
Lakeland Regional Cancer Center, Lakeland, Florida, United States
🇺🇸Cancer Centers of the Carolinas, Greenville, South Carolina, United States
🇺🇸Gunderson Clinic, La Crosse, Wisconsin, United States
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00502112
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸St.Vincent's Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyeloproliferative DisordersMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT00283114
- Locations
- 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.